Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + CyBorD in newly diagnosed AL amyloidosis
NCT03201965Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2017
- Primary completion
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 3, randomised trial of daratumumab in amyloid light chain amyloidosis (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Complete Hematologic Response at 2.4 years. Started Oct 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT03201965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03201965.